Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China

Fineline Cube Aug 11, 2023

China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a...

Company Drug

NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma

Fineline Cube Aug 11, 2023

The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...

Company Medical Device

Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China

Fineline Cube Aug 11, 2023

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China,...

Company Deals

WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership

Fineline Cube Aug 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Deals

Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China

Fineline Cube Aug 11, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...

Company

Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales

Fineline Cube Aug 11, 2023

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...

Company Legal / IP

Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China

Fineline Cube Aug 11, 2023

A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...

Company

Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars

Fineline Cube Aug 10, 2023

US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...

Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Company Deals

Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy

Fineline Cube Aug 10, 2023

US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002

Fineline Cube Aug 10, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Medical Device

Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China

Fineline Cube Aug 10, 2023

Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...

Company Deals

Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development

Fineline Cube Aug 10, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...

Company Drug

Novartis Reports Positive Phase III Results for Remibrutinib in Chronic Spontaneous Urticaria

Fineline Cube Aug 10, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has announced positive data from the Phase III...

Company Deals

Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies

Fineline Cube Aug 9, 2023

Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...

Company Policy / Regulatory

Audit Reveals Illicit Payments and Inflated Prices in Pharmaceutical Industry

Fineline Cube Aug 9, 2023

An audit has shed light on the use of third-party business promotion companies as a...

Company

Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 9, 2023

US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...

Company

FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising

Fineline Cube Aug 9, 2023

US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...

Company

Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals

Fineline Cube Aug 9, 2023

Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...

Posts pagination

1 … 513 514 515 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.